Highbridge Capital Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Highbridge Capital Management’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-38,340	Closed	-$210K	–	1376
2018 Q1	$210K	Buy	38,340 +12,836	+50%	+$90.4K	﹤0.01%	1046
2017 Q4	$208K	Buy	+25,504	New	+$244K	﹤0.01%	1485
2017 Q3	–	Sell	-10,841	Closed	-$119K	–	1828
2017 Q2	$119K	Buy	+10,841	New	+$101K	﹤0.01%	1164
2016 Q3	–	Sell	-38,676	Closed	-$231K	–	1743
2016 Q2	$231K	Buy	+38,676	New	+$215K	﹤0.01%	1180

Other funds holding ENZ

EGA

Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Highbridge Capital Management's ENZ Position: Q2 2018 in Review

Highbridge Capital Management sold out of Enzo Biochem, Inc. (ENZ) in Q2 2018, closing a stake of 38,340 shares — an estimated $210K sold.

Highbridge Capital Management first reported a position in ENZ in Q2 2016 and held it in 4 quarters. The position peaked at $231K in Q2 2016. 97 funds tracked by Wall St. Rank hold ENZ as of Q2 2018.

Highbridge Capital Management reported no remaining Enzo Biochem, Inc. position as of Q2 2018 after selling out during the quarter.
Highbridge Capital Management sold 38,340 Enzo Biochem, Inc. shares in Q2 2018, an estimated $210K.
Highbridge Capital Management first reported a position in Enzo Biochem, Inc. in Q2 2016 and held it in 4 quarters.
Highbridge Capital Management's Enzo Biochem, Inc. position peaked at $231K in Q2 2016.
97 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.